CYP2C19 and myocardial infarction: Participants felt strongly that pre-emptive PGx testing via the GP was preferable to point of care testing in hospital at the time of indication for therapeutic (ie in the example of CYP2C19 testing to help guide anti-platelet choice after a myocardial infarction).